Theranostics Market By Product (Diagnostic imaging, Radiopharmaceuticals, IVD/Biomarker screening, Software and services), By Application (Prostate cancer, Bone metastasis, Neuroendocrine tumors, Lymphoma, Cardiovascular diseases, Other Applications), By End-user (Hospitals, Diagnostics centers, Specialty clinics, Other end-users), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2024-2033
-
47163
-
June 2024
-
300
-
-
This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Report Overview
The Theranostics Market was valued at USD 3.0 Billion in 2023. It is expected to reach USD 10.5 Billion by 2033, with a CAGR of 13.7% during the forecast period from 2024 to 2033.
The theranostics market, at the intersection of therapeutic and diagnostic innovations, is revolutionizing personalized medicine by integrating diagnostic testing and therapeutic interventions. This market encompasses advanced technologies like molecular imaging and targeted therapy, enabling precise disease diagnosis, real-time monitoring, and individualized treatment plans.
The theranostics market is witnessing a transformative evolution, driven by the confluence of advanced diagnostics and targeted therapeutic interventions. The integration of nanotechnology into theranostics represents a significant leap forward, enhancing both diagnostic precision and therapeutic efficacy. Over the past five years, research publications and patents related to nano-theranostics have surged by an estimated 20% annually, underscoring the burgeoning interest and investment in this domain. This trend is not merely academic; it signals a paradigm shift in clinical practice, where the ability to diagnose and treat diseases at the molecular level is becoming increasingly feasible. The rise in chronic diseases, such as cancer and cardiovascular ailments, further propels the demand for innovative theranostic solutions, as they promise more personalized and effective treatment modalities.
Key market drivers underscore the robust growth trajectory of the theranostics sector. The increasing prevalence of chronic diseases necessitates more precise and personalized medical interventions, which theranostics can uniquely provide. Advances in molecular imaging technologies are pivotal, enabling earlier and more accurate disease detection, which in turn facilitates timely and targeted therapeutic responses.
Additionally, global healthcare expenditure is on an upward trajectory, reflecting a broader commitment to integrating cutting-edge medical technologies into routine clinical care. Collectively, these factors position the theranostics market for sustained growth, as stakeholders from research institutions to healthcare providers recognize the profound potential of this integrated approach to revolutionizing patient care. The strategic focus on nanotechnology and personalized medicine within theranostics not only aligns with current healthcare trends but also sets a new standard for the future of medical diagnostics and therapy.
Key Takeaways
- Market Growth: The Theranostics Market was valued at USD 3.0 Billion in 2023. It is expected to reach USD 10.5 Billion by 2033, with a CAGR of 13.7% during the forecast period from 2024 to 2033.
- By Product: Diagnostic Imaging dominated theranostics with a 32% market share.
- By Application: Prostate Cancer dominated Theranostics with over 25% share.
- By End-User: Hospitals dominated the theranostics market with over 38% share.
- Regional Dominance: North America dominates the theranostics market with a 35% share.
- Growth Opportunity: Precision medicine and diagnostic imaging advancements drive theranostics market growth.
Driving factors
Surge in Cancer and Chronic Illness Incidences Fuels Theranostics Market Expansion
The increasing prevalence of cancer and chronic illnesses is a significant driver of the theranostics market. With over 18 million new cancer cases diagnosed worldwide in 2020 and chronic diseases accounting for 71% of all deaths globally, there is a pressing need for innovative diagnostic and therapeutic solutions.
Theranostics, which integrates therapeutic and diagnostic capabilities into a single platform, offers a promising approach to addressing these health challenges. This integrated method allows for more personalized and effective treatments, leading to better patient outcomes and increased demand for theranostic solutions. The surge in these diseases directly correlates with the growing adoption of theranostics, as healthcare providers seek more efficient ways to diagnose and treat complex conditions.
Boost in Biological Research Investments Accelerates Theranostics Advancements
Increased investments in biological research significantly contribute to the growth of the theranostics market. Governments, private organizations, and academic institutions are funneling substantial resources into the study of biology and related fields, driving innovation and technological advancements. For instance, global research and development (R&D) spending in the pharmaceutical industry reached approximately $200 billion in 2021.
This influx of funding supports the development of new theranostic technologies, from advanced imaging techniques to novel biomarkers. Enhanced research capabilities facilitate the discovery of more targeted and effective theranostic applications, thereby accelerating market growth. The synergy between investment and innovation in biological research creates a robust pipeline of theranostic products poised to meet the rising demand for personalized medicine.
Demand for Technology-Driven Pharmaceutical Production Spurs Theranostics Adoption
The growing need for contemporary technology-based pharmaceutical production is another crucial factor driving the theranostics market. The pharmaceutical industry is increasingly leveraging advanced technologies such as artificial intelligence (AI), big data analytics, and nanotechnology to enhance drug development processes and outcomes.
These technologies are pivotal in the production of theranostics, enabling precise targeting and efficient treatment regimens. The shift towards high-tech pharmaceutical manufacturing supports the scalability and integration of theranostic solutions into mainstream healthcare. By improving the accuracy and efficacy of diagnostics and therapies, modern technology not only enhances patient care but also drives market growth through increased adoption and trust in theranostic products.
Restraining Factors
Short Half-Life of Radiopharmaceuticals: A Key Challenge in Theranostics Market Expansion
The short half-life of radiopharmaceuticals represents a significant challenge for the theranostics market. Radiopharmaceuticals, crucial for both diagnostic imaging and therapeutic applications, rapidly lose their radioactivity, which limits their shelf life and necessitates immediate use post-manufacture. This constraint not only complicates logistics but also restricts the geographical reach of these products.
The logistical complexities are particularly pronounced for facilities located far from production sites. The need for timely transportation to ensure efficacy means that healthcare providers in remote or less-developed regions might struggle to access these advanced diagnostic and therapeutic options. Consequently, this limits the potential market size and hampers global expansion.
High Cost of Theranostics Procedures: Barrier to Broad Adoption
The high cost of theranostics procedures is another critical factor restraining the growth of this market. Theranostics, which combines diagnostic imaging and targeted therapy, involves advanced technologies and specialized skills, resulting in substantial expenses. These costs include not only the production of radiopharmaceuticals but also the infrastructure required for imaging and therapy, the expertise needed for accurate administration, and the safety protocols for handling radioactive materials.
For instance, the production of radiopharmaceuticals involves complex processes and stringent regulatory requirements, which drive up the costs. Furthermore, the integration of diagnostic and therapeutic capabilities often requires significant investment in state-of-the-art imaging equipment, such as PET/CT or SPECT/CT scanners, and trained personnel to operate them.
By Product Analysis
In 2023, Diagnostic Imaging dominated theranostics with a 32% market share.
In 2023, Diagnostic Imaging held a dominant market position in the By Product segment of the Theranostics Market, capturing more than a 32% share. This was driven by the critical role of imaging technologies in early disease detection and precise treatment planning. The segment's robust growth is fueled by advancements in MRI, CT scans, and PET imaging, which enhance the accuracy and effectiveness of theranostic applications.
Radiopharmaceuticals followed closely, benefiting from increased adoption of targeted radionuclide therapies and diagnostic agents, underscoring their integral role in personalized medicine. The rising prevalence of cancer and cardiovascular diseases has propelled the demand for radiopharmaceuticals, solidifying their market presence.
IVD/Biomarker Screening emerged as a vital component, leveraging the growth of precision medicine. Biomarkers facilitate early detection and individualized treatment strategies, significantly impacting patient outcomes. Innovations in genomic and proteomic technologies have further augmented this segment’s relevance.
Lastly, Software and Services supported the integration and analysis of complex data, optimizing theranostic workflows. Advanced analytics, AI-driven insights, and cloud-based solutions have revolutionized patient management and treatment efficacy, driving substantial market growth in this segment. Together, these segments synergistically advance the theranostics field, promising enhanced patient care and clinical outcomes.
By Application Analysis
In 2023, Prostate Cancer dominated Theranostics with over 25% share.
In 2023, Prostate Cancer held a dominant market position in the By Application segment of the Theranostics Market, capturing more than a 25% share. This prevalence is driven by the high incidence and substantial clinical focus on improving diagnostics and targeted therapies for prostate cancer, reflecting robust investments in R&D and the introduction of novel theranostic agents.
Bone metastasis applications also demonstrate significant market traction. As a common complication of advanced cancers, bone metastasis theranostics benefit from advancements in imaging and personalized treatment options, enhancing patient outcomes and driving market growth.
Neuroendocrine tumors represent another critical segment. The rising prevalence of these tumors and the development of specific theranostic radiopharmaceuticals have bolstered market demand, supported by growing awareness and diagnostic precision.
In the Lymphoma segment, innovative theranostic approaches are revolutionizing treatment paradigms, combining diagnostic imaging with targeted therapies to improve prognosis and patient management. Cardiovascular disease applications are gaining momentum as theranostic technologies expand beyond oncology. The integration of diagnostic imaging and therapeutic interventions promises improved management of cardiac conditions, driving market expansion.
Lastly, Other applications, including infectious diseases and autoimmune disorders, are emerging as key areas for theranostic development. Continuous innovation and cross-disciplinary applications are expected to further diversify and strengthen this market segment.
By End-user Analysis
Hospitals dominated the theranostics market with over 38% share.
In 2023, Hospitals held a dominant market position in the end-user segment of the theranostics market, capturing more than a 38% share. This dominance is attributed to the comprehensive integration of diagnostic and therapeutic services within hospital settings, providing a one-stop solution for patients requiring complex care. The robust infrastructure and advanced technology available in hospitals further enhance their capacity to deliver precise and effective theranostic treatments.
Diagnostics centers followed closely, benefiting from their specialized focus on early disease detection and personalized medicine. These centers accounted for a significant market share due to their proficiency in deploying state-of-the-art imaging and molecular diagnostic tools, essential for theranostics.
Specialty clinics also made substantial contributions, leveraging their expertise in niche medical areas such as oncology and cardiology. These clinics are often at the forefront of adopting innovative theranostic approaches, tailored to meet specific patient needs.
Other end-users, including academic institutions and research laboratories, played a crucial role in advancing theranostic technologies through ongoing research and development efforts. Their contributions are vital for the continuous evolution and adoption of theranostics in clinical practice.
Key Market Segments
By Product
- Diagnostic imaging
- MRI
- PET imaging
- Nuclear imaging
- CT scan
- Others
- Radiopharmaceuticals
- Lutetium-177
- Samarium-153
- Radium-223
- Iodine-131
- Yttrium-90
- Gallium-68
- Fluorine-18
- Others
- IVD/Biomarker screening
- Polymerase chain reaction (PCR)
- Next-generation sequencing (NGS)
- Fluorescence in-situ hybridization (FISH)
- Software and services
By Application
- Prostate cancer
- Bone metastasis
- Neuroendocrine tumors
- Lymphoma
- Cardiovascular diseases
- Other Applications
By End-user
- Hospitals
- Diagnostics centers
- Specialty clinics
- Other end-users
Growth Opportunity
Growing Demand for Personalized Medicine
The global theranostics market stands at a pivotal juncture in 2024, driven significantly by the growing demand for personalized medicine. Personalized medicine, which tailors treatment to individual patient characteristics, is transforming healthcare by enhancing the efficacy of treatments and reducing adverse effects. Theranostics, integrating therapeutic and diagnostic capabilities into a single platform, is at the forefront of this evolution. The ability to diagnose and treat diseases simultaneously facilitates more precise and effective healthcare interventions. This synergy not only accelerates patient recovery but also optimizes healthcare resource utilization, presenting a compelling growth opportunity for market players.
Rising Prevalence of Chronic Diseases
Another critical factor propelling the theranostics market is the rising prevalence of chronic diseases. Conditions such as cancer, cardiovascular diseases, and diabetes are becoming increasingly common, necessitating advanced diagnostic and therapeutic solutions. Theranostics offers a dual benefit in managing these chronic conditions: accurate diagnostics enable early detection, while targeted therapies ensure efficient treatment. This dual capability is particularly advantageous in oncology, where theranostic agents can identify and treat tumors with high specificity, improving patient outcomes and survival rates. As chronic disease rates continue to climb globally, the demand for innovative theranostic solutions is expected to surge, driving market expansion.
Latest Trends
Rising Focus on Precision Medicine
The theranostics market in 2024 is witnessing significant momentum driven by the increasing emphasis on precision medicine. As healthcare systems worldwide shift towards more personalized treatment protocols, theranostics integrating diagnostics with therapeutics offers a tailored approach to patient care. This trend is supported by advances in genomics, proteomics, and metabolomics, enabling clinicians to devise highly specific treatment regimens. By leveraging biomarker-based diagnostics, healthcare providers can identify patient-specific disease characteristics, thereby optimizing therapeutic efficacy and minimizing adverse effects.
The adoption of precision medicine is particularly evident in oncology, where theranostics facilitates targeted therapy, improving patient outcomes and cost-efficiency. As regulatory frameworks evolve to accommodate these innovations, the precision medicine paradigm is poised to become a cornerstone of modern healthcare.
Advancements in Diagnostic Imaging
Technological advancements in diagnostic imaging are another key trend propelling the theranostics market forward. Enhanced imaging modalities such as PET, MRI, and CT scans are integral to the theranostic approach, providing detailed insights into disease pathology and progression. Innovations in imaging agents and techniques have significantly improved the accuracy and resolution of diagnostic imaging, enabling early detection and precise localization of disease. These advancements are crucial for the effective delivery of targeted therapies, as they allow for real-time monitoring of therapeutic efficacy and disease response.
Furthermore, the integration of artificial intelligence and machine learning in imaging technologies is revolutionizing diagnostic capabilities, offering predictive analytics and personalized treatment planning. This convergence of advanced imaging and theranostics is set to drive substantial growth in the market, as it aligns with the broader healthcare objective of delivering precise and effective patient care.
Regional Analysis
North America dominates the theranostics market with a 35% share.
The global theranostics market, segmented by region, reveals distinct growth patterns and dominant players. North America leads the market with a commanding 35% share, driven by advanced healthcare infrastructure, significant R&D investments, and high adoption rates of innovative diagnostic and therapeutic solutions. The presence of major pharmaceutical and biotechnology firms further propels the market, alongside favorable government policies and funding initiatives supporting personalized medicine.
Europe follows, underpinned by strong healthcare systems, increasing cancer prevalence, and supportive regulatory frameworks. The region benefits from robust collaborations between research institutions and industry players, enhancing the development and commercialization of theranostic solutions.
In the Asia Pacific region, rapid market expansion is observed due to growing healthcare expenditures, rising awareness of personalized medicine, and increasing prevalence of chronic diseases. Countries like China and India are emerging as significant markets due to their large patient populations and improving healthcare infrastructures.
The Middle East & Africa region, though smaller in market size, is witnessing gradual growth driven by improving healthcare access and growing investments in healthcare technology. Latin America shows potential with rising healthcare investments and an increasing focus on advanced diagnostics and treatment methods.
Key Regions and Countries
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Netherlands
- Russia
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- Singapore
- Thailand
- South Korea
- Vietnam
- India
- New Zealand
- Rest of Asia Pacific
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of the Middle East & Africa
Key Players Analysis
The global theranostics market in 2024 is poised for significant growth, driven by advancements in precision medicine and the integration of diagnostic and therapeutic capabilities. Key players in this sector are well-positioned to leverage their extensive portfolios and innovative capabilities to capture market share and drive technological progress.
Bayer AG continues to innovate in the pharmaceutical and biotechnology spaces, with a strong focus on oncology and cardiovascular therapies, aligning with theranostics' dual diagnostic and therapeutic approach. Beckman Coulter, Inc., a leader in clinical diagnostics, provides robust platforms for biomarker discovery, enhancing precision in disease treatment.
Cardinal Health, Inc.'s extensive distribution network and supply chain capabilities are crucial for the widespread adoption of theranostics. Canon Medical Systems Corporation and GE HealthCare Technologies Inc. bring advanced imaging solutions to the table, facilitating accurate diagnostics crucial for effective theranostic applications.
Curium and Lantheus Holdings, Inc. are pivotal in radiopharmaceuticals, a cornerstone of theranostic procedures, particularly in oncology. F. Hoffmann La Roche Ltd. and Thermo Fisher Scientific Inc. lead in molecular diagnostics and personalized medicine, driving innovations that underpin theranostic strategies.
Koninklijke Philips N.V. and Siemens Healthineers AG leverage their expertise in imaging and diagnostics to integrate therapeutic solutions, offering comprehensive theranostic approaches. These companies, along with other key players, are instrumental in shaping a future where theranostics becomes central to patient-centric care, offering precise, tailored treatment options.
Market Key Players
- Bayer AG
- Beckman Coulter, Inc.
- Cardinal Health, Inc.
- Canon Medical Systems Corporation
- Curium
- F. Hoffmann La Roche Ltd.
- GE Healthcare Technologies Inc.
- Koninklijke Philips N.V.
- Lantheus Holdings, Inc.
- Siemens Healthnieers AG
- Thermo Fisher Scientific Inc.
- Other Key Player
Recent Development
- In April 2024, Siemens Healthineers unveiled a new software platform that integrates diagnostic and therapeutic data, facilitating personalized treatment plans. This platform leverages AI to enhance the accuracy of theranostic procedures, marking a substantial advancement in precision medicine
- In March 2024, Bayer announced the launch of a new theranostic radiopharmaceutical aimed at treating prostate cancer. This product integrates advanced diagnostic imaging and targeted therapy, enhancing precision in both diagnosing and treating prostate cancer.
- In February 2024, GE Healthcare introduced a novel diagnostic imaging system specifically designed for theranostics applications. This system improves the accuracy of imaging while reducing the time needed for both diagnosis and treatment planning, particularly in oncology.
Report Scope
Report Features Description Market Value (2023) USD 3.0 Billion Forecast Revenue (2033) USD 10.7 Billion CAGR (2024-2032) 13.7% Base Year for Estimation 2023 Historic Period 2016-2023 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Product (Diagnostic imaging, Radiopharmaceuticals, IVD/Biomarker screening, Software and services), By Application (Prostate cancer, Bone metastasis, Neuroendocrine tumors, Lymphoma, Cardiovascular diseases, Other Applications), By End-user (Hospitals, Diagnostics centers, Specialty clinics, Other end-users) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Bayer AG, Beckman Coulter, Inc., Cardinal Health, Inc., Canon Medical Systems Corporation, Curium, F. Hoffmann La Roche Ltd., GE HealthCare Technologies Inc., Koninklijke Philips N.V., Lantheus Holdings, Inc., Siemens Healthnieers AG, Thermo Fisher Scientific Inc., Other Key Player Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
- 1. Executive Summary
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 1.4. Key Analysis
- 1.5. Key Findings by Major Segments
- 1.6. Top strategies by Major Players
- 2. Global Theranostics Market Overview
- 2.1. Theranostics Market Dynamics
- 2.1.1. Drivers
- 2.1.2. Opportunities
- 2.1.3. Restraints
- 2.1.4. Challenges
- 2.2. Macro-economic Factors
- 2.3. Regulatory Framework
- 2.4. Market Investment Feasibility Index
- 2.5. PEST Analysis
- 2.6. PORTER’S Five Force Analysis
- 2.7. Drivers & Restraints Impact Analysis
- 2.8. Industry Chain Analysis
- 2.9. Cost Structure Analysis
- 2.10. Marketing Strategy
- 2.11. Russia-Ukraine War Impact Analysis
- 2.12. Opportunity Map Analysis
- 2.13. Market Competition Scenario Analysis
- 2.14. Product Life Cycle Analysis
- 2.15. Opportunity Orbits
- 2.16. Manufacturer Intensity Map
- 2.17. Major Companies sales by Value & Volume
- 2.1. Theranostics Market Dynamics
- 3. Global Theranostics Market Analysis, Opportunity and Forecast, 2016-2032
- 3.1. Global Theranostics Market Analysis, 2016-2021
- 3.2. Global Theranostics Market Opportunity and Forecast, 2023-2032
- 3.3. Global Theranostics Market Analysis, Opportunity and Forecast, By Product, 2016-2032
- 3.3.1. Global Theranostics Market Analysis by Product: Introduction
- 3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product, 2016-2032
- 3.3.3. Diagnostic imaging
- 3.3.3.1. MRI
- 3.3.3.2. PET imaging
- 3.3.3.3. Nuclear imaging
- 3.3.3.4. CT scan
- 3.3.3.5. Others
- 3.3.4. Radiopharmaceuticals
- 3.3.4.1. Lutetium-177
- 3.3.4.2. Samarium-153
- 3.3.4.3. Radium-223
- 3.3.4.4. Iodine-131
- 3.3.4.5. Yttrium-90
- 3.3.5. IVD/Biomarker screeening
- 3.3.5.1. Polymerase chain reaction (PCR)
- 3.3.5.2. Next-generation sequencing (NGS)
- 3.3.5.3. Fluorescence in-situ hybridization (FISH)
- 3.3.6. Software and services
- 3.4. Global Theranostics Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 3.4.1. Global Theranostics Market Analysis by Application: Introduction
- 3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 3.4.3. Prostate cancer
- 3.4.4. Bone metastasis
- 3.4.5. Neuroendocrine tumors
- 3.4.6. Lymphoma
- 3.4.7. Cardiovascular diseases
- 3.4.8. Other applications
- 3.5. Global Theranostics Market Analysis, Opportunity and Forecast, By End-user, 2016-2032
- 3.5.1. Global Theranostics Market Analysis by End-user: Introduction
- 3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-user, 2016-2032
- 3.5.3. Hospitals
- 3.5.4. Diagnostics centers
- 3.5.5. Specialty clinics
- 3.5.6. Other end-users
- 4. North America Theranostics Market Analysis, Opportunity and Forecast, 2016-2032
- 4.1. North America Theranostics Market Analysis, 2016-2021
- 4.2. North America Theranostics Market Opportunity and Forecast, 2023-2032
- 4.3. North America Theranostics Market Analysis, Opportunity and Forecast, By Product, 2016-2032
- 4.3.1. North America Theranostics Market Analysis by Product: Introduction
- 4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product, 2016-2032
- 4.3.3. Diagnostic imaging
- 4.3.3.1. MRI
- 4.3.3.2. PET imaging
- 4.3.3.3. Nuclear imaging
- 4.3.3.4. CT scan
- 4.3.3.5. Others
- 4.3.4. Radiopharmaceuticals
- 4.3.4.1. Lutetium-177
- 4.3.4.2. Samarium-153
- 4.3.4.3. Radium-223
- 4.3.4.4. Iodine-131
- 4.3.4.5. Yttrium-90
- 4.3.5. IVD/Biomarker screeening
- 4.3.5.1. Polymerase chain reaction (PCR)
- 4.3.5.2. Next-generation sequencing (NGS)
- 4.3.5.3. Fluorescence in-situ hybridization (FISH)
- 4.3.6. Software and services
- 4.4. North America Theranostics Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 4.4.1. North America Theranostics Market Analysis by Application: Introduction
- 4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 4.4.3. Prostate cancer
- 4.4.4. Bone metastasis
- 4.4.5. Neuroendocrine tumors
- 4.4.6. Lymphoma
- 4.4.7. Cardiovascular diseases
- 4.4.8. Other applications
- 4.5. North America Theranostics Market Analysis, Opportunity and Forecast, By End-user, 2016-2032
- 4.5.1. North America Theranostics Market Analysis by End-user: Introduction
- 4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-user, 2016-2032
- 4.5.3. Hospitals
- 4.5.4. Diagnostics centers
- 4.5.5. Specialty clinics
- 4.5.6. Other end-users
- 4.6. North America Theranostics Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 4.6.1. North America Theranostics Market Analysis by Country : Introduction
- 4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 4.6.2.1. The US
- 4.6.2.2. Canada
- 4.6.2.3. Mexico
- 5. Western Europe Theranostics Market Analysis, Opportunity and Forecast, 2016-2032
- 5.1. Western Europe Theranostics Market Analysis, 2016-2021
- 5.2. Western Europe Theranostics Market Opportunity and Forecast, 2023-2032
- 5.3. Western Europe Theranostics Market Analysis, Opportunity and Forecast, By Product, 2016-2032
- 5.3.1. Western Europe Theranostics Market Analysis by Product: Introduction
- 5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product, 2016-2032
- 5.3.3. Diagnostic imaging
- 5.3.3.1. MRI
- 5.3.3.2. PET imaging
- 5.3.3.3. Nuclear imaging
- 5.3.3.4. CT scan
- 5.3.3.5. Others
- 5.3.4. Radiopharmaceuticals
- 5.3.4.1. Lutetium-177
- 5.3.4.2. Samarium-153
- 5.3.4.3. Radium-223
- 5.3.4.4. Iodine-131
- 5.3.4.5. Yttrium-90
- 5.3.5. IVD/Biomarker screeening
- 5.3.5.1. Polymerase chain reaction (PCR)
- 5.3.5.2. Next-generation sequencing (NGS)
- 5.3.5.3. Fluorescence in-situ hybridization (FISH)
- 5.3.6. Software and services
- 5.4. Western Europe Theranostics Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 5.4.1. Western Europe Theranostics Market Analysis by Application: Introduction
- 5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 5.4.3. Prostate cancer
- 5.4.4. Bone metastasis
- 5.4.5. Neuroendocrine tumors
- 5.4.6. Lymphoma
- 5.4.7. Cardiovascular diseases
- 5.4.8. Other applications
- 5.5. Western Europe Theranostics Market Analysis, Opportunity and Forecast, By End-user, 2016-2032
- 5.5.1. Western Europe Theranostics Market Analysis by End-user: Introduction
- 5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-user, 2016-2032
- 5.5.3. Hospitals
- 5.5.4. Diagnostics centers
- 5.5.5. Specialty clinics
- 5.5.6. Other end-users
- 5.6. Western Europe Theranostics Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 5.6.1. Western Europe Theranostics Market Analysis by Country : Introduction
- 5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 5.6.2.1. Germany
- 5.6.2.2. France
- 5.6.2.3. The UK
- 5.6.2.4. Spain
- 5.6.2.5. Italy
- 5.6.2.6. Portugal
- 5.6.2.7. Ireland
- 5.6.2.8. Austria
- 5.6.2.9. Switzerland
- 5.6.2.10. Benelux
- 5.6.2.11. Nordic
- 5.6.2.12. Rest of Western Europe
- 6. Eastern Europe Theranostics Market Analysis, Opportunity and Forecast, 2016-2032
- 6.1. Eastern Europe Theranostics Market Analysis, 2016-2021
- 6.2. Eastern Europe Theranostics Market Opportunity and Forecast, 2023-2032
- 6.3. Eastern Europe Theranostics Market Analysis, Opportunity and Forecast, By Product, 2016-2032
- 6.3.1. Eastern Europe Theranostics Market Analysis by Product: Introduction
- 6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product, 2016-2032
- 6.3.3. Diagnostic imaging
- 6.3.3.1. MRI
- 6.3.3.2. PET imaging
- 6.3.3.3. Nuclear imaging
- 6.3.3.4. CT scan
- 6.3.3.5. Others
- 6.3.4. Radiopharmaceuticals
- 6.3.4.1. Lutetium-177
- 6.3.4.2. Samarium-153
- 6.3.4.3. Radium-223
- 6.3.4.4. Iodine-131
- 6.3.4.5. Yttrium-90
- 6.3.5. IVD/Biomarker screeening
- 6.3.5.1. Polymerase chain reaction (PCR)
- 6.3.5.2. Next-generation sequencing (NGS)
- 6.3.5.3. Fluorescence in-situ hybridization (FISH)
- 6.3.6. Software and services
- 6.4. Eastern Europe Theranostics Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 6.4.1. Eastern Europe Theranostics Market Analysis by Application: Introduction
- 6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 6.4.3. Prostate cancer
- 6.4.4. Bone metastasis
- 6.4.5. Neuroendocrine tumors
- 6.4.6. Lymphoma
- 6.4.7. Cardiovascular diseases
- 6.4.8. Other applications
- 6.5. Eastern Europe Theranostics Market Analysis, Opportunity and Forecast, By End-user, 2016-2032
- 6.5.1. Eastern Europe Theranostics Market Analysis by End-user: Introduction
- 6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-user, 2016-2032
- 6.5.3. Hospitals
- 6.5.4. Diagnostics centers
- 6.5.5. Specialty clinics
- 6.5.6. Other end-users
- 6.6. Eastern Europe Theranostics Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 6.6.1. Eastern Europe Theranostics Market Analysis by Country : Introduction
- 6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 6.6.2.1. Russia
- 6.6.2.2. Poland
- 6.6.2.3. The Czech Republic
- 6.6.2.4. Greece
- 6.6.2.5. Rest of Eastern Europe
- 7. APAC Theranostics Market Analysis, Opportunity and Forecast, 2016-2032
- 7.1. APAC Theranostics Market Analysis, 2016-2021
- 7.2. APAC Theranostics Market Opportunity and Forecast, 2023-2032
- 7.3. APAC Theranostics Market Analysis, Opportunity and Forecast, By Product, 2016-2032
- 7.3.1. APAC Theranostics Market Analysis by Product: Introduction
- 7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product, 2016-2032
- 7.3.3. Diagnostic imaging
- 7.3.3.1. MRI
- 7.3.3.2. PET imaging
- 7.3.3.3. Nuclear imaging
- 7.3.3.4. CT scan
- 7.3.3.5. Others
- 7.3.4. Radiopharmaceuticals
- 7.3.4.1. Lutetium-177
- 7.3.4.2. Samarium-153
- 7.3.4.3. Radium-223
- 7.3.4.4. Iodine-131
- 7.3.4.5. Yttrium-90
- 7.3.5. IVD/Biomarker screeening
- 7.3.5.1. Polymerase chain reaction (PCR)
- 7.3.5.2. Next-generation sequencing (NGS)
- 7.3.5.3. Fluorescence in-situ hybridization (FISH)
- 7.3.6. Software and services
- 7.4. APAC Theranostics Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 7.4.1. APAC Theranostics Market Analysis by Application: Introduction
- 7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 7.4.3. Prostate cancer
- 7.4.4. Bone metastasis
- 7.4.5. Neuroendocrine tumors
- 7.4.6. Lymphoma
- 7.4.7. Cardiovascular diseases
- 7.4.8. Other applications
- 7.5. APAC Theranostics Market Analysis, Opportunity and Forecast, By End-user, 2016-2032
- 7.5.1. APAC Theranostics Market Analysis by End-user: Introduction
- 7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-user, 2016-2032
- 7.5.3. Hospitals
- 7.5.4. Diagnostics centers
- 7.5.5. Specialty clinics
- 7.5.6. Other end-users
- 7.6. APAC Theranostics Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 7.6.1. APAC Theranostics Market Analysis by Country : Introduction
- 7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 7.6.2.1. China
- 7.6.2.2. Japan
- 7.6.2.3. South Korea
- 7.6.2.4. India
- 7.6.2.5. Australia & New Zeland
- 7.6.2.6. Indonesia
- 7.6.2.7. Malaysia
- 7.6.2.8. Philippines
- 7.6.2.9. Singapore
- 7.6.2.10. Thailand
- 7.6.2.11. Vietnam
- 7.6.2.12. Rest of APAC
- 8. Latin America Theranostics Market Analysis, Opportunity and Forecast, 2016-2032
- 8.1. Latin America Theranostics Market Analysis, 2016-2021
- 8.2. Latin America Theranostics Market Opportunity and Forecast, 2023-2032
- 8.3. Latin America Theranostics Market Analysis, Opportunity and Forecast, By Product, 2016-2032
- 8.3.1. Latin America Theranostics Market Analysis by Product: Introduction
- 8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product, 2016-2032
- 8.3.3. Diagnostic imaging
- 8.3.3.1. MRI
- 8.3.3.2. PET imaging
- 8.3.3.3. Nuclear imaging
- 8.3.3.4. CT scan
- 8.3.3.5. Others
- 8.3.4. Radiopharmaceuticals
- 8.3.4.1. Lutetium-177
- 8.3.4.2. Samarium-153
- 8.3.4.3. Radium-223
- 8.3.4.4. Iodine-131
- 8.3.4.5. Yttrium-90
- 8.3.5. IVD/Biomarker screeening
- 8.3.5.1. Polymerase chain reaction (PCR)
- 8.3.5.2. Next-generation sequencing (NGS)
- 8.3.5.3. Fluorescence in-situ hybridization (FISH)
- 8.3.6. Software and services
- 8.4. Latin America Theranostics Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 8.4.1. Latin America Theranostics Market Analysis by Application: Introduction
- 8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 8.4.3. Prostate cancer
- 8.4.4. Bone metastasis
- 8.4.5. Neuroendocrine tumors
- 8.4.6. Lymphoma
- 8.4.7. Cardiovascular diseases
- 8.4.8. Other applications
- 8.5. Latin America Theranostics Market Analysis, Opportunity and Forecast, By End-user, 2016-2032
- 8.5.1. Latin America Theranostics Market Analysis by End-user: Introduction
- 8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-user, 2016-2032
- 8.5.3. Hospitals
- 8.5.4. Diagnostics centers
- 8.5.5. Specialty clinics
- 8.5.6. Other end-users
- 8.6. Latin America Theranostics Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 8.6.1. Latin America Theranostics Market Analysis by Country : Introduction
- 8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 8.6.2.1. Brazil
- 8.6.2.2. Colombia
- 8.6.2.3. Chile
- 8.6.2.4. Argentina
- 8.6.2.5. Costa Rica
- 8.6.2.6. Rest of Latin America
- 9. Middle East & Africa Theranostics Market Analysis, Opportunity and Forecast, 2016-2032
- 9.1. Middle East & Africa Theranostics Market Analysis, 2016-2021
- 9.2. Middle East & Africa Theranostics Market Opportunity and Forecast, 2023-2032
- 9.3. Middle East & Africa Theranostics Market Analysis, Opportunity and Forecast, By Product, 2016-2032
- 9.3.1. Middle East & Africa Theranostics Market Analysis by Product: Introduction
- 9.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Product, 2016-2032
- 9.3.3. Diagnostic imaging
- 9.3.3.1. MRI
- 9.3.3.2. PET imaging
- 9.3.3.3. Nuclear imaging
- 9.3.3.4. CT scan
- 9.3.3.5. Others
- 9.3.4. Radiopharmaceuticals
- 9.3.4.1. Lutetium-177
- 9.3.4.2. Samarium-153
- 9.3.4.3. Radium-223
- 9.3.4.4. Iodine-131
- 9.3.4.5. Yttrium-90
- 9.3.5. IVD/Biomarker screeening
- 9.3.5.1. Polymerase chain reaction (PCR)
- 9.3.5.2. Next-generation sequencing (NGS)
- 9.3.5.3. Fluorescence in-situ hybridization (FISH)
- 9.3.6. Software and services
- 9.4. Middle East & Africa Theranostics Market Analysis, Opportunity and Forecast, By Application, 2016-2032
- 9.4.1. Middle East & Africa Theranostics Market Analysis by Application: Introduction
- 9.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Application, 2016-2032
- 9.4.3. Prostate cancer
- 9.4.4. Bone metastasis
- 9.4.5. Neuroendocrine tumors
- 9.4.6. Lymphoma
- 9.4.7. Cardiovascular diseases
- 9.4.8. Other applications
- 9.5. Middle East & Africa Theranostics Market Analysis, Opportunity and Forecast, By End-user, 2016-2032
- 9.5.1. Middle East & Africa Theranostics Market Analysis by End-user: Introduction
- 9.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-user, 2016-2032
- 9.5.3. Hospitals
- 9.5.4. Diagnostics centers
- 9.5.5. Specialty clinics
- 9.5.6. Other end-users
- 9.6. Middle East & Africa Theranostics Market Analysis, Opportunity and Forecast, By Country , 2016-2032
- 9.6.1. Middle East & Africa Theranostics Market Analysis by Country : Introduction
- 9.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
- 9.6.2.1. Algeria
- 9.6.2.2. Egypt
- 9.6.2.3. Israel
- 9.6.2.4. Kuwait
- 9.6.2.5. Nigeria
- 9.6.2.6. Saudi Arabia
- 9.6.2.7. South Africa
- 9.6.2.8. Turkey
- 9.6.2.9. The UAE
- 9.6.2.10. Rest of MEA
- 10. Global Theranostics Market Analysis, Opportunity and Forecast, By Region , 2016-2032
- 10.1. Global Theranostics Market Analysis by Region : Introduction
- 10.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
- 10.2.1. North America
- 10.2.2. Western Europe
- 10.2.3. Eastern Europe
- 10.2.4. APAC
- 10.2.5. Latin America
- 10.2.6. Middle East & Africa
- 11. Global Theranostics Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 11.1. Market Share Analysis
- 11.2. Company Profiles
- 11.3. Bayer AG
- 11.3.1. Company Overview
- 11.3.2. Financial Highlights
- 11.3.3. Product Portfolio
- 11.3.4. SWOT Analysis
- 11.3.5. Key Strategies and Developments
- 11.4. Beckman Coulter, Inc.
- 11.4.1. Company Overview
- 11.4.2. Financial Highlights
- 11.4.3. Product Portfolio
- 11.4.4. SWOT Analysis
- 11.4.5. Key Strategies and Developments
- 11.5. Cardinal Health, Inc.
- 11.5.1. Company Overview
- 11.5.2. Financial Highlights
- 11.5.3. Product Portfolio
- 11.5.4. SWOT Analysis
- 11.5.5. Key Strategies and Developments
- 11.6. Canon Medical Systems Corporation
- 11.6.1. Company Overview
- 11.6.2. Financial Highlights
- 11.6.3. Product Portfolio
- 11.6.4. SWOT Analysis
- 11.6.5. Key Strategies and Developments
- 11.7. Curium
- 11.7.1. Company Overview
- 11.7.2. Financial Highlights
- 11.7.3. Product Portfolio
- 11.7.4. SWOT Analysis
- 11.7.5. Key Strategies and Developments
- 11.8. F. Hoffmann La Roche Ltd.
- 11.8.1. Company Overview
- 11.8.2. Financial Highlights
- 11.8.3. Product Portfolio
- 11.8.4. SWOT Analysis
- 11.8.5. Key Strategies and Developments
- 11.9. GE HealthCare Technologies Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Highlights
- 11.9.3. Product Portfolio
- 11.9.4. SWOT Analysis
- 11.9.5. Key Strategies and Developments
- 11.10. Koninklijke Philips N.V.
- 11.10.1. Company Overview
- 11.10.2. Financial Highlights
- 11.10.3. Product Portfolio
- 11.10.4. SWOT Analysis
- 11.10.5. Key Strategies and Developments
- 11.11. Lantheus Holdings, Inc.
- 11.11.1. Company Overview
- 11.11.2. Financial Highlights
- 11.11.3. Product Portfolio
- 11.11.4. SWOT Analysis
- 11.11.5. Key Strategies and Developments
- 11.12. Siemens Healthnieers AG
- 11.12.1. Company Overview
- 11.12.2. Financial Highlights
- 11.12.3. Product Portfolio
- 11.12.4. SWOT Analysis
- 11.12.5. Key Strategies and Developments
- 11.13.1. Company Overview
- 11.13.2. Financial Highlights
- 11.13.3. Product Portfolio
- 11.13.4. SWOT Analysis
- 11.13.5. Key Strategies and Developments
- 11.14. Thermo Fisher Scientific Inc.
- 11.14.1. Company Overview
- 11.14.2. Financial Highlights
- 11.14.3. Product Portfolio
- 11.14.4. SWOT Analysis
- 11.14.5. Key Strategies and Developments
- 12. Assumptions and Acronyms
- 13. Research Methodology
- 14. Contact
"
- List of Figures
- "
- Figure 1: Global Theranostics Market Revenue (US$ Mn) Market Share by Product in 2022
- Figure 2: Global Theranostics Market Market Attractiveness Analysis by Product, 2016-2032
- Figure 3: Global Theranostics Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 4: Global Theranostics Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 5: Global Theranostics Market Revenue (US$ Mn) Market Share by End-userin 2022
- Figure 6: Global Theranostics Market Market Attractiveness Analysis by End-user, 2016-2032
- Figure 7: Global Theranostics Market Revenue (US$ Mn) Market Share by Region in 2022
- Figure 8: Global Theranostics Market Market Attractiveness Analysis by Region, 2016-2032
- Figure 9: Global Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Figure 10: Global Theranostics Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Figure 11: Global Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Figure 12: Global Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 13: Global Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Figure 14: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Figure 15: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Figure 16: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 17: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Figure 18: Global Theranostics Market Market Share Comparison by Region (2016-2032)
- Figure 19: Global Theranostics Market Market Share Comparison by Product (2016-2032)
- Figure 20: Global Theranostics Market Market Share Comparison by Application (2016-2032)
- Figure 21: Global Theranostics Market Market Share Comparison by End-user (2016-2032)
- Figure 22: North America Theranostics Market Revenue (US$ Mn) Market Share by Productin 2022
- Figure 23: North America Theranostics Market Market Attractiveness Analysis by Product, 2016-2032
- Figure 24: North America Theranostics Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 25: North America Theranostics Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 26: North America Theranostics Market Revenue (US$ Mn) Market Share by End-userin 2022
- Figure 27: North America Theranostics Market Market Attractiveness Analysis by End-user, 2016-2032
- Figure 28: North America Theranostics Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 29: North America Theranostics Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 30: North America Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Figure 31: North America Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 32: North America Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Figure 33: North America Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 34: North America Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Figure 35: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 36: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Figure 37: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 38: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Figure 39: North America Theranostics Market Market Share Comparison by Country (2016-2032)
- Figure 40: North America Theranostics Market Market Share Comparison by Product (2016-2032)
- Figure 41: North America Theranostics Market Market Share Comparison by Application (2016-2032)
- Figure 42: North America Theranostics Market Market Share Comparison by End-user (2016-2032)
- Figure 43: Western Europe Theranostics Market Revenue (US$ Mn) Market Share by Productin 2022
- Figure 44: Western Europe Theranostics Market Market Attractiveness Analysis by Product, 2016-2032
- Figure 45: Western Europe Theranostics Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 46: Western Europe Theranostics Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 47: Western Europe Theranostics Market Revenue (US$ Mn) Market Share by End-userin 2022
- Figure 48: Western Europe Theranostics Market Market Attractiveness Analysis by End-user, 2016-2032
- Figure 49: Western Europe Theranostics Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 50: Western Europe Theranostics Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 51: Western Europe Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Figure 52: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 53: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Figure 54: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 55: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Figure 56: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 57: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Figure 58: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 59: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Figure 60: Western Europe Theranostics Market Market Share Comparison by Country (2016-2032)
- Figure 61: Western Europe Theranostics Market Market Share Comparison by Product (2016-2032)
- Figure 62: Western Europe Theranostics Market Market Share Comparison by Application (2016-2032)
- Figure 63: Western Europe Theranostics Market Market Share Comparison by End-user (2016-2032)
- Figure 64: Eastern Europe Theranostics Market Revenue (US$ Mn) Market Share by Productin 2022
- Figure 65: Eastern Europe Theranostics Market Market Attractiveness Analysis by Product, 2016-2032
- Figure 66: Eastern Europe Theranostics Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 67: Eastern Europe Theranostics Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 68: Eastern Europe Theranostics Market Revenue (US$ Mn) Market Share by End-userin 2022
- Figure 69: Eastern Europe Theranostics Market Market Attractiveness Analysis by End-user, 2016-2032
- Figure 70: Eastern Europe Theranostics Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 71: Eastern Europe Theranostics Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 72: Eastern Europe Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Figure 73: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 74: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Figure 75: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 76: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Figure 77: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 78: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Figure 79: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 80: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Figure 81: Eastern Europe Theranostics Market Market Share Comparison by Country (2016-2032)
- Figure 82: Eastern Europe Theranostics Market Market Share Comparison by Product (2016-2032)
- Figure 83: Eastern Europe Theranostics Market Market Share Comparison by Application (2016-2032)
- Figure 84: Eastern Europe Theranostics Market Market Share Comparison by End-user (2016-2032)
- Figure 85: APAC Theranostics Market Revenue (US$ Mn) Market Share by Productin 2022
- Figure 86: APAC Theranostics Market Market Attractiveness Analysis by Product, 2016-2032
- Figure 87: APAC Theranostics Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 88: APAC Theranostics Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 89: APAC Theranostics Market Revenue (US$ Mn) Market Share by End-userin 2022
- Figure 90: APAC Theranostics Market Market Attractiveness Analysis by End-user, 2016-2032
- Figure 91: APAC Theranostics Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 92: APAC Theranostics Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 93: APAC Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Figure 94: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 95: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Figure 96: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 97: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Figure 98: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 99: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Figure 100: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 101: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Figure 102: APAC Theranostics Market Market Share Comparison by Country (2016-2032)
- Figure 103: APAC Theranostics Market Market Share Comparison by Product (2016-2032)
- Figure 104: APAC Theranostics Market Market Share Comparison by Application (2016-2032)
- Figure 105: APAC Theranostics Market Market Share Comparison by End-user (2016-2032)
- Figure 106: Latin America Theranostics Market Revenue (US$ Mn) Market Share by Productin 2022
- Figure 107: Latin America Theranostics Market Market Attractiveness Analysis by Product, 2016-2032
- Figure 108: Latin America Theranostics Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 109: Latin America Theranostics Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 110: Latin America Theranostics Market Revenue (US$ Mn) Market Share by End-userin 2022
- Figure 111: Latin America Theranostics Market Market Attractiveness Analysis by End-user, 2016-2032
- Figure 112: Latin America Theranostics Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 113: Latin America Theranostics Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 114: Latin America Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Figure 115: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 116: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Figure 117: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 118: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Figure 119: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 120: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Figure 121: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 122: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Figure 123: Latin America Theranostics Market Market Share Comparison by Country (2016-2032)
- Figure 124: Latin America Theranostics Market Market Share Comparison by Product (2016-2032)
- Figure 125: Latin America Theranostics Market Market Share Comparison by Application (2016-2032)
- Figure 126: Latin America Theranostics Market Market Share Comparison by End-user (2016-2032)
- Figure 127: Middle East & Africa Theranostics Market Revenue (US$ Mn) Market Share by Productin 2022
- Figure 128: Middle East & Africa Theranostics Market Market Attractiveness Analysis by Product, 2016-2032
- Figure 129: Middle East & Africa Theranostics Market Revenue (US$ Mn) Market Share by Applicationin 2022
- Figure 130: Middle East & Africa Theranostics Market Market Attractiveness Analysis by Application, 2016-2032
- Figure 131: Middle East & Africa Theranostics Market Revenue (US$ Mn) Market Share by End-userin 2022
- Figure 132: Middle East & Africa Theranostics Market Market Attractiveness Analysis by End-user, 2016-2032
- Figure 133: Middle East & Africa Theranostics Market Revenue (US$ Mn) Market Share by Country in 2022
- Figure 134: Middle East & Africa Theranostics Market Market Attractiveness Analysis by Country, 2016-2032
- Figure 135: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Figure 136: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Figure 137: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Figure 138: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Figure 139: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Figure 140: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Figure 141: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Figure 142: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Figure 143: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Figure 144: Middle East & Africa Theranostics Market Market Share Comparison by Country (2016-2032)
- Figure 145: Middle East & Africa Theranostics Market Market Share Comparison by Product (2016-2032)
- Figure 146: Middle East & Africa Theranostics Market Market Share Comparison by Application (2016-2032)
- Figure 147: Middle East & Africa Theranostics Market Market Share Comparison by End-user (2016-2032)
"
- List of Tables
- "
- Table 1: Global Theranostics Market Market Comparison by Product (2016-2032)
- Table 2: Global Theranostics Market Market Comparison by Application (2016-2032)
- Table 3: Global Theranostics Market Market Comparison by End-user (2016-2032)
- Table 4: Global Theranostics Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 5: Global Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Table 6: Global Theranostics Market Market Revenue (US$ Mn) Comparison by Region (2016-2032)
- Table 7: Global Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Table 8: Global Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 9: Global Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Table 10: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
- Table 11: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Table 12: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 13: Global Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Table 14: Global Theranostics Market Market Share Comparison by Region (2016-2032)
- Table 15: Global Theranostics Market Market Share Comparison by Product (2016-2032)
- Table 16: Global Theranostics Market Market Share Comparison by Application (2016-2032)
- Table 17: Global Theranostics Market Market Share Comparison by End-user (2016-2032)
- Table 18: North America Theranostics Market Market Comparison by Application (2016-2032)
- Table 19: North America Theranostics Market Market Comparison by End-user (2016-2032)
- Table 20: North America Theranostics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 21: North America Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Table 22: North America Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 23: North America Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Table 24: North America Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 25: North America Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Table 26: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 27: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Table 28: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 29: North America Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Table 30: North America Theranostics Market Market Share Comparison by Country (2016-2032)
- Table 31: North America Theranostics Market Market Share Comparison by Product (2016-2032)
- Table 32: North America Theranostics Market Market Share Comparison by Application (2016-2032)
- Table 33: North America Theranostics Market Market Share Comparison by End-user (2016-2032)
- Table 34: Western Europe Theranostics Market Market Comparison by Product (2016-2032)
- Table 35: Western Europe Theranostics Market Market Comparison by Application (2016-2032)
- Table 36: Western Europe Theranostics Market Market Comparison by End-user (2016-2032)
- Table 37: Western Europe Theranostics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 38: Western Europe Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Table 39: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 40: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Table 41: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 42: Western Europe Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Table 43: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 44: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Table 45: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 46: Western Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Table 47: Western Europe Theranostics Market Market Share Comparison by Country (2016-2032)
- Table 48: Western Europe Theranostics Market Market Share Comparison by Product (2016-2032)
- Table 49: Western Europe Theranostics Market Market Share Comparison by Application (2016-2032)
- Table 50: Western Europe Theranostics Market Market Share Comparison by End-user (2016-2032)
- Table 51: Eastern Europe Theranostics Market Market Comparison by Product (2016-2032)
- Table 52: Eastern Europe Theranostics Market Market Comparison by Application (2016-2032)
- Table 53: Eastern Europe Theranostics Market Market Comparison by End-user (2016-2032)
- Table 54: Eastern Europe Theranostics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 55: Eastern Europe Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Table 56: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 57: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Table 58: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 59: Eastern Europe Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Table 60: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 61: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Table 62: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 63: Eastern Europe Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Table 64: Eastern Europe Theranostics Market Market Share Comparison by Country (2016-2032)
- Table 65: Eastern Europe Theranostics Market Market Share Comparison by Product (2016-2032)
- Table 66: Eastern Europe Theranostics Market Market Share Comparison by Application (2016-2032)
- Table 67: Eastern Europe Theranostics Market Market Share Comparison by End-user (2016-2032)
- Table 68: APAC Theranostics Market Market Comparison by Product (2016-2032)
- Table 69: APAC Theranostics Market Market Comparison by Application (2016-2032)
- Table 70: APAC Theranostics Market Market Comparison by End-user (2016-2032)
- Table 71: APAC Theranostics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 72: APAC Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Table 73: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 74: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Table 75: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 76: APAC Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Table 77: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 78: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Table 79: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 80: APAC Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Table 81: APAC Theranostics Market Market Share Comparison by Country (2016-2032)
- Table 82: APAC Theranostics Market Market Share Comparison by Product (2016-2032)
- Table 83: APAC Theranostics Market Market Share Comparison by Application (2016-2032)
- Table 84: APAC Theranostics Market Market Share Comparison by End-user (2016-2032)
- Table 85: Latin America Theranostics Market Market Comparison by Product (2016-2032)
- Table 86: Latin America Theranostics Market Market Comparison by Application (2016-2032)
- Table 87: Latin America Theranostics Market Market Comparison by End-user (2016-2032)
- Table 88: Latin America Theranostics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 89: Latin America Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Table 90: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 91: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Table 92: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 93: Latin America Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Table 94: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 95: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Table 96: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 97: Latin America Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Table 98: Latin America Theranostics Market Market Share Comparison by Country (2016-2032)
- Table 99: Latin America Theranostics Market Market Share Comparison by Product (2016-2032)
- Table 100: Latin America Theranostics Market Market Share Comparison by Application (2016-2032)
- Table 101: Latin America Theranostics Market Market Share Comparison by End-user (2016-2032)
- Table 102: Middle East & Africa Theranostics Market Market Comparison by Product (2016-2032)
- Table 103: Middle East & Africa Theranostics Market Market Comparison by Application (2016-2032)
- Table 104: Middle East & Africa Theranostics Market Market Comparison by End-user (2016-2032)
- Table 105: Middle East & Africa Theranostics Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 106: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) (2016-2032)
- Table 107: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by Country (2016-2032)
- Table 108: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by Product (2016-2032)
- Table 109: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by Application (2016-2032)
- Table 110: Middle East & Africa Theranostics Market Market Revenue (US$ Mn) Comparison by End-user (2016-2032)
- Table 111: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
- Table 112: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by Product (2016-2032)
- Table 113: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by Application (2016-2032)
- Table 114: Middle East & Africa Theranostics Market Market Y-o-Y Growth Rate Comparison by End-user (2016-2032)
- Table 115: Middle East & Africa Theranostics Market Market Share Comparison by Country (2016-2032)
- Table 116: Middle East & Africa Theranostics Market Market Share Comparison by Product (2016-2032)
- Table 117: Middle East & Africa Theranostics Market Market Share Comparison by Application (2016-2032)
- Table 118: Middle East & Africa Theranostics Market Market Share Comparison by End-user (2016-2032)
- 1. Executive Summary
-
- Bayer AG
- Beckman Coulter, Inc.
- Cardinal Health, Inc.
- Canon Medical Systems Corporation
- Curium
- F. Hoffmann La Roche Ltd.
- GE Healthcare Technologies Inc.
- Koninklijke Philips N.V.
- Lantheus Holdings, Inc.
- Siemens Healthnieers AG
- Thermo Fisher Scientific Inc.
- Other Key Player
Our Clients
View Our Licence Options
